Recombinant plasma proteins
Tóm tắt
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins–such as coagulation factors, anticoagulants, immunoglobulins, and albumin – essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible – although with some limitations in productivity, costs, and immunogenic risks – to produce and commercialize complex plasma glycoproteins for human therapeutic applications and has opened the way to the development of new molecular entities. Today, the advanced exploration of alternative cell lines and enhanced cell culture systems, as well as the development of alternative expression technologies, such as transgenic animals, is opening a new era in the production of the full range of recombinant plasma protein therapeutics. In this review, we examine the achievements and ongoing challenges of the recombinant DNA technology as a platform for the production of plasma proteins and the advantages and limitations of such products compared to fractionated plasma proteins.
Từ khóa
Tài liệu tham khảo
Weidner M, 2010, Expression of recombinant proteins in the methylotrophic yeast Pichia pastoris, J Vis Exp, 36
Echelard Y, 2006, Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals, Biopharm Int, 19, 36
Kaufman RJ, 1986, Expression, purification, and characterization of recombinant gamma‐carboxylated factor IX synthesized in Chinese hamster ovary cells, J Biol Chem, 261, 9622, 10.1016/S0021-9258(18)67559-3
White G, 1998, Clinical evaluation of recombinant factor IX, Semin Hematol, 35, 33
Eaton DL, 1987, Characterization of recombinant human factor VIII, J Biol Chem, 262, 3285, 10.1016/S0021-9258(18)61502-9
Turecek PL, 2009, Development of a plasma‐ and albumin‐free recombinant von Willebrand factor, Hamostaseologie, 29, S32
Townsend RR, 1982, Carbohydrate structure of human fibrinogen. Use of 300‐MHz 1H‐NMR to characterize glycosidase‐treated glycopeptides, J Biol Chem, 257, 9704, 10.1016/S0021-9258(18)34130-9
Mintz PD, 2001, Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center, Ann Clin Lab Sci, 31, 108
Butler SP, 1997, Current progress in the production of recombinant human fibrinogen in the milk of transgenic animals, Thromb Haemost, 78, 537, 10.1055/s-0038-1657584
Semple E, 2005, Quality of thrombin produced from the patient’s own plasma using the TPD, a new Thrombin‐processing Device, J Extra Corpor Technol, 37, 196, 10.1051/ject/200537196
Rodgers GM, 2009, Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency An update, Thromb Haemost, 101, 806, 10.1160/TH08-10-0672
Berry LR, 2009, Comparison of recombinant and plasma‐derived antithrombin biodistribution in a rabbit model, Thromb Haemost, 102, 302, 10.1160/TH09-01-0062
Caliezi C, 2000, C1‐Esterase inhibitor: an anti‐inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema, Pharmacol Rev, 52, 91
WHO, 2003, Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products
Dodsworth N, 1996, Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation, Biotechnol Appl Biochem, 24, 171, 10.1111/j.1470-8744.1996.tb00397.x
Tuddenham EGD, 2010, From human to humans – introducing the first recombinant human FVIII product produced from a human cell line, Thromb Haemost, 103, 4